Novartis To Present New Data On Multiple Sclerosis Treatment

Mayzent is an oral treatment for relapse remitting MS and active secondary progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Novartis To Present New Data On Multiple Sclerosis Treatment

Post by MSUK » Wed Mar 13, 2013 12:46 am

Novartis AG said it will present new data on Multiple Sclerosis or MS treatment at the 65th annual meeting of the American Academy of Neurology or AAN.

It will highlight growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS or RMS. Updates on studies of Gilenya in people with primary-progressive MS or PPMS and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS or SPMS will also be communicated, the company said... Read More - http://www.ms-uk.org/index.cfm/gilenya
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post